Standalone figures · ₹ crore · years without a filed annual are summed from quarters
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,322 | 3,313 | 4,155 | 5,117 | 5,951 | 5,390 | 6,596 | 6,641 | 7,919 | 9,038 | 9,826 | |
| COGS | -1,463 | -1,617 | 1,999 | 2,072 | 2,308 | 1,472 | 1,920 | 1,582 | 2,146 | 2,407 | 2,662 |
| Gross profit | — | — | 2,156 | 3,045 | 3,643 | 3,918 | 4,676 | 5,059 | 5,773 | 6,631 | 7,164 |
| 3,595 | 4,679 | 1,831 | 2,625 | 3,253 | 3,660 | 4,424 | 4,761 | 5,375 | 6,124 | 6,518 | |
| 190 | 251 | 325 | 420 | 391 | 258 | 252 | 298 | 398 | 507 | 647 | |
| OPM % | 8.2% | 7.6% | 7.8% | 8.2% | 6.6% | 4.8% | 3.8% | 4.5% | 5% | 5.6% | 6.6% |
| Depreciation | 57 | 68 | 69 | 72 | 79 | 76 | 76 | 90 | 101 | 115 | 155 |
| Interest | 133 | 122 | 118 | 136 | 137 | 73 | 62 | 95 | 121 | 164 | 167 |
| -53 | 7 | 10 | 17 | 12 | 34 | 237 | 10 | 26 | 15 | 43 | |
| Profit before tax | -52 | 54 | 149 | 229 | 188 | 143 | 352 | 123 | 202 | 242 | 367 |
| Tax | -18 | 9 | 50 | 81 | 59 | 58 | 66 | 24 | 50 | 61 | 84 |
| Tax % | -34.9% | 17.5% | 34% | 35.2% | 31.6% | 40.9% | 18.8% | 19.5% | 24.9% | 25.4% | 23% |
| -34 | 45 | 98 | 148 | 128 | 84 | 285 | 99 | 152 | 180 | 282 | |
| PAT margin % | -1.5% | 1.3% | 2.4% | 2.9% | 2.2% | 1.6% | 4.3% | 1.5% | 1.9% | 2% | 2.9% |
| EPS (₹) | -11 | 14.4 | 31.7 | 47.9 | 41.4 | 27.2 | 92.2 | 31.9 | 49 | 58.3 | 44.3 |
| EPS adjusted (₹) | — | 7.2 | 15.8 | 23.9 | 20.7 | 13.6 | 46.1 | 16 | 24.5 | 29.1 | 42.1 |
| — | 7% | 12.6% | 12.5% | 14.5% | 22% | 8.1% | 23.5% | 16.3% | 8.6% | — | |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 34 |
| Reserves | 815 | 910 | 1,043 | — | 1,214 | 1,481 | 1,557 | 1,685 | 1,840 | 2,504 |
| 852 | 687 | 792 | — | 1,050 | 962 | 1,094 | 1,321 | 1,804 | 1,578 | |
| 1,665 | 1,717 | 1,849 | — | 1,779 | 1,793 | 1,862 | 2,244 | 2,115 | 2,010 | |
| Total equity & liabilities | 3,363 | 3,345 | 3,715 | — | 4,074 | 4,267 | 4,543 | 5,281 | 5,790 | 6,126 |
| 2,002 | 2,052 | 2,066 | 2,126 | 2,094 | 2,224 | 2,709 | 3,198 | 3,827 | 4,553 | |
| CWIP | 78 | 76 | 124 | — | 119 | 237 | 125 | 84 | 98 | 37 |
| Investments | 26 | 26 | 26 | — | 37 | 36 | 9 | 7 | 2 | 2 |
| 1,258 | 1,191 | 1,500 | — | 1,824 | 1,770 | 1,700 | 1,993 | 1,863 | 1,535 | |
| Total assets | 3,363 | 3,345 | 3,715 | — | 4,074 | 4,267 | 4,543 | 5,281 | 5,790 | 6,126 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Potable Spirits | 6,946.43 | 284.93 | 596.6 | 326.53 | 270.07 | 105.5 |
| Bio-Fuel | 1,469.93 | 115.23 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 302 | 487 | 148 | 294 | 86 | 90 | 326 | 438 | 362 | 769 | |
| -41 | -145 | -133 | -152 | -140 | 93 | -330 | -503 | -736 | -767 | |
| -261 | -342 | 7 | -165 | 54 | -180 | -0 | 90 | 354 | 23 | |
| Net cash flow | — | — | — | — | 0 | 4 | -5 | 25 | -20 | 25 |
| Free cash flow | 260 | — | — | — | -66 | -290 | 322 | 428 | 354 | 762 |
| CFO / Operating profit % | 120.5% | 150% | 35.4% | 75.1% | 33.2% | 35.6% | 109.5% | 110.2% | 71.4% | 118.9% |
| 1,429.96 |
| 92.27 |
| 1,337.69 |
| 8.61 |
| Bio-based Specialities and Performance Chemicals | 1,202.07 | 138.27 | 3,595.99 | 737.05 | 2,858.94 | 4.84 |
| Ennature Biopharma | 207.77 | 7.23 | 426.42 | 92.49 | 333.93 | 2.17 |
₹ crore by fiscal year